Comments on: Amylin, Alkermes Sit in Suspense For FDA Verdict on Once-Weekly Diabetes Drug

By: Amylin, Alkermes Diabetes Drug Delayed by FDA | Xconomy « Mendium Diabetes

Mon, 15 Mar 2010 14:00:23 +0000

[...] The drug application is being closely watched because it takes the active ingredient in Amylin’s best-selling drug and combines it with a biodegradable polymer technology from Waltham, MA-based Alkermes (NASDAQ: ALKS) that makes it last longer in the blood. That polymer is the difference between an existing drug that must be injected twice a day and the newer form, which only requires one shot a week. The product will be marketed under the name Bydureon, the companies said. [...]

By: Arthur

Arthur — Fri, 12 Mar 2010 17:04:05 +0000

The last paragraph makes the most sense!!

By: SAIC Gets Navy Contract With More Than $625M Potential « NCTimes.com Blogs

SAIC Gets Navy Contract With More Than $625M Potential « NCTimes.com Blogs — Wed, 10 Mar 2010 14:31:50 +0000

[...] Amylin, Alkermes Await FDA Verdict on Once-Weekly Diabetes Drug From Xconomy’s Luke Timmerman [...]